Sinohealth Technology reported revenue of RMB 161.51 million for the six months ended 30 June 2026, up 9.2% year-on-year, driven by the initial commercialisation of AI agent products and continued expansion of data-driven services.
Gross profit rose 10.0% to RMB 90.33 million, with gross margin stable at 55.9% (H1 2025: 55.5%). However, net profit attributable to shareholders plunged 86.1% to RMB 2.65 million, as R&D expenses climbed 17.3% to RMB 38.75 million and net foreign-exchange losses widened to RMB 12.39 million. Operating profit contracted 46.6% to RMB 8.67 million, while finance income dropped because of lower USD and RMB rates, leading to a 22.0% decline in other income and gains to RMB 10.25 million.
By segment, Commercial Solutions contributed RMB 126.61 million (+9.9%), Data-driven Publications and Events RMB 33.24 million (+1.6%), and AI applications RMB 16.85 million (+295.0%). Rapid growth in AI revenues reflects embedding large-language-model capabilities into core products such as CHIS and Linghe. Medical big-data services generated RMB 9.60 million, more than doubling year-on-year.
Cost of sales increased 8.1% to RMB 71.18 million, broadly in line with top-line expansion. Selling and distribution expenses rose 22.1% to RMB 21.44 million as the company stepped up marketing to support new AI offerings. Administrative expenses edged up 5.9% to RMB 15.09 million, while impairment losses on financial assets widened to RMB 6.38 million.
Total assets reached RMB 846.21 million (+2.5% versus year-end 2025), but cash and cash equivalents fell 57.8% to RMB 98.55 million after sizeable allocations to low-risk wealth-management products and time deposits. The gearing ratio stood at 16.1% (31 Dec 2025: 15.0%) with no bank borrowings outstanding.
The board declared no interim dividend. A final dividend of HK$7.12 cents per share (RMB 28.00 million) for FY 2025 was approved on 18 June 2026 and is reflected in dividend payables.
Sinohealth reiterated its January 2026 strategic shift to become an “AI technology services company” anchored on healthcare data and ecosystem resources. During the period it launched multiple AI agents—GHIC for commercial decision-making, MedMate for doctors, upgraded SIC for pharmacies, and piloted Deep Pharma for R&D decision support—aiming to build new revenue streams across R&D, commercial growth, medical services and consumer health.
The company plans to deploy remaining net proceeds of HK$199.70 million from its 2022 IPO mainly on AI product enhancement, technology R&D, and strategic investments by December 2028.
Comments